Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

Vaccination following spinal cord injury: Innovative approach limits paralysis

Weizmann Institute Of Science : 15 August, 2001  (Company News)
Weizmann Institute scientists propose an innovative approach for preventing complete paralysis after partial spinal cord injury. The approach consists of boosting the body's natural immune mechanisms to improve the outcome of trauma. The team of Prof. Michal Schwartz of the Weizmann Institute's Neurobiology Department has in the past already developed one immune-based therapy for the spinal cord, currently tested in humans by Proneuron Biotechnologies Ltd. That therapy is aimed at repairing the spinal cord after a complete injury. The new approach pursues a related but different therapeutic target: to limit degeneration after a partial spinal cord injury. The scientists report their latest results in the August 15 issue of the Journal of Clinical Investigation.
Weizmann Institute scientists propose an innovative approach for preventing complete paralysis after partial spinal cord injury. The approach consists of boosting the body's natural immune mechanisms to improve the outcome of trauma.

The team of Prof. Michal Schwartz of the Weizmann Institute's Neurobiology Department has in the past already developed one immune-based therapy for the spinal cord, currently tested in humans by Proneuron Biotechnologies Ltd. That therapy is aimed at repairing the spinal cord after a complete injury. The new approach pursues a related but different therapeutic target: to limit degeneration after a partial spinal cord injury. The scientists report their latest results in the August 15 issue of the Journal of Clinical Investigation.

Following injury to the central nervous system (brain or spinal cord), a wave of damage spreads from the injury site over several days or weeks, killing nerve cells and fibers that survived the initial trauma. This secondary degeneration can be even more destructive than the initial damage. As a result, an injury that initially inflicted only partial damage on the nerve tissue in the spinal cord may eventually result in total paralysis.

In the United States alone, approximately 10,000 people sustain a spinal cord injury each year. More than half of these injuries are classified as incomplete, or partial, meaning that some nerve fibers survived the initial trauma. If the surviving tissue could be protected against secondary degeneration, this would significantly improve the final outcome.

In the past, Schwartz and colleagues showed that autoimmune T cells, the white blood cells of the immune system that interact with the body's own tissues, have a protective effect on damaged tissue in the spinal cord, reducing secondary degeneration. This protective response is the body's own way of minimizing the consequences of trauma. However, the naturally occurring T-cell response is restricted in its effectiveness.

In the new study, rats were vaccinated soon after severe partial injury to the spinal cord with peptides, or protein fragments, derived from the central nervous system. The peptides were selected so that they would boost the natural protective mechanisms of the immune system without triggering an autoimmune disease. Rats vaccinated with the peptides showed significant recovery of movement. Tissue analysis revealed that the treated animals had substantially more healthy nerve fibers in the spinal cord than the untreated rats, suggesting that the treatment protected the animals from secondary degeneration. Results indicate that the therapeutic window for T-cell-based treatment is at least on week after injury. This approach may also prove effective in other disorders of the central nervous system, such as stroke or traumatic brain injury.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo